Anti-SMAD7 antibody produced in rabbit

Anti-SMAD7 has been used in western blot analysis and immunofluorescence.

SMAD7 (mothers against decapentaplegic homolog 7) is a modulator of TGFβ (transforming growth factorβ) signaling in immune cells which are associated with ulcerative colitis and inflammatory bowel syndrome. It plays a major role in the etiology of CRC (colorectal cancer). In addition, it also acts as a mediator of the negative feedback loop for both the TGFβ and BMP (bone morphogenetic proteins) signaling pathways. It is essential for the remodelling of pharyngeal artery and the enlargement of great vessel. In mouse, homozygous removal of Smad7 causes primarily fourth-related arch artery defects. Silencing of Smad7 in RCD (refractory coeliac disease) biopsy samples can decrease the expression of interleukin-6 and tumour necrosis factor-α. Polymorphism of this gene is associated with colorectal cancer. SMAD7 is an inhibitor of the TGFβ (transforming growth factor beta) /BMP (bone morphogenetic proteins) pathway.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

SMAD7 (mothers against decapentaplegic homolog 7) is a Tbx1 (T-box 1) interacting gene and is encoded by the gene mapped to human chromosome 18q21.1.

peptide corresponding to an internal region of human SMAD7, conjugated to KLH. The corresponding sequence is identical in monkey, mouse, rat and bovine

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.